1FARID N A, PAYNE C D, SMALL D S, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [ J ]. Clin Pharmacol Ther, 2007, 81 (5):735-741.
2FDA. Label approved on 07/10/2009 for EFFIENT,NDA no. 022307 [EB/OL]. http: //www. accessdata. fda. gov/drugsatfda-docs/labelZ 2009/022307s0001bl. pdf.
3JAKUBOWSKI J A, PAYNE C D, WEERAKKODY G J, et al. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects[ J]. J Cardiovasc Pharmacol, 2007, 49 (3) : 167-173.
4WALLENTIN L, VARENHORST C, JAMES S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibi- tion than clopidogrel due to more effcient generation of its active metabolite in aspirin-treated patients with coronary artery disease [J]. Eur Heart J, 2008, 29(1):21-30.
5WIVIOTT S D, BRAUNWALD E, MCCABE C H, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes[ J]. N Engl J Med, 2007, 357(20):2001-2015.
4Jakubowski JA, Winters K J, Naganuma H, et al. Prasugrel : a novel thienopyridine antiplatelet agent. A review of preclinical and clin- ical studies and the mechanistic basis for its distinct antiplatelet profile[ J]. Cardiovascular Drug Rev, 2007, 25 (4): 357.
5Alain B, Daniel F,Jian-Pierre M ,et al. Derivatives of alpha(2-oxo- 2,4,5,6,7,7a-hexahy drothieno [ 3,2-c] -5-pyridyl) phenyl acetic acid,and their use as platelet and thrombotic aggregation inhibi- tiors [ P ]. US. 4740510,1988 04-26.
6Hiroyuki K, Fumitoshi A, Atsuhiro S,et al. Tetra-hydrothienopyri- dine derivatives, furo and pyrrolo analogs thereof and their prepa- ration and uses for inhibiting blood platelet aggregation [ P ]. EP 0542411,1993-05-19.
